Aptevo Therapeutics (APVO) Cash & Equivalents (2016 - 2023)
Historic Cash & Equivalents for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $19.1 million.
- Aptevo Therapeutics' Cash & Equivalents fell 1535.63% to $19.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $19.1 million, marking a year-over-year decrease of 1535.63%. This contributed to the annual value of $22.6 million for FY2022, which is 5111.55% down from last year.
- Per Aptevo Therapeutics' latest filing, its Cash & Equivalents stood at $19.1 million for Q3 2023, which was down 1535.63% from $21.0 million recorded in Q2 2023.
- In the past 5 years, Aptevo Therapeutics' Cash & Equivalents ranged from a high of $61.7 million in Q2 2021 and a low of $7.6 million during Q2 2020
- In the last 5 years, Aptevo Therapeutics' Cash & Equivalents had a median value of $24.9 million in 2020 and averaged $30.5 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 6688.01% in 2020, then surged by 71133.04% in 2021.
- Over the past 5 years, Aptevo Therapeutics' Cash & Equivalents (Quarter) stood at $19.9 million in 2019, then skyrocketed by 113.25% to $42.5 million in 2020, then grew by 8.86% to $46.3 million in 2021, then tumbled by 51.12% to $22.6 million in 2022, then fell by 15.57% to $19.1 million in 2023.
- Its Cash & Equivalents stands at $19.1 million for Q3 2023, versus $21.0 million for Q2 2023 and $25.3 million for Q1 2023.